Fresenius Medical Care AG (XTER:FME) ROCE %

: 6.40% (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fresenius Medical Care AG's annualized ROCE % for the quarter that ended in Dec. 2023 was 6.40%.

Fresenius Medical Care AG ROCE % Historical Data

The historical data trend for Fresenius Medical Care AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius Medical Care AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

10.17

9.11

7.30

5.60

5.11

Fresenius Medical Care AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																4.91	3.75	5.31	4.87	6.40

Fresenius Medical Care AG ROCE % Calculation

Fresenius Medical Care AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1457.655	/	( ( (35754.114 - 6467.314)	+	(33929.808 - 6111.59) )	/ 2 )
	=	1457.655	/	( (29286.8	+	27818.218)	/ 2 )
	=	1457.655	/	28552.509
	=	5.11 %

Fresenius Medical Care AG's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	1818.048	/	( ( (35634.696 - 6619.331)	+	(33929.808 - 6111.59) )	/ 2 )
	=	1818.048	/	( ( 29015.365	+	27818.218 )	/ 2 )
	=	1818.048	/	28416.7915
	=	6.40 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Fresenius Medical Care AG (XTER:FME) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Fresenius Medical Care AG ROCE % Related Terms

Thank you for viewing the detailed overview of Fresenius Medical Care AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresenius Medical Care AG (XTER:FME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (XTER:FME) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

FMCQF:USA FMS:USA FME:Italy FMEd:UK 0H9X:UK FMSC34:Brazil FME:Austria

Address

Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352

Website

https://www.freseniusmedicalcare.com

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Executives

Dr. Katarzyna Mazur-hofsäß	Board of Directors
Harry De Wit	Board of Directors
Dr. Olaf Schermeier	Board of Directors

Fresenius Medical Care AG (XTER:FME) Headlines

No Headlines